Αποτελέσματα Αναζήτησης
DESCRIPTION. ORTHO EVRA® is a combination transdermal contraceptive patch with a contact surface area of 20 cm2. It contains 6.00 mg norelgestromin (NGMN) and 0.75 mg ethinyl estradiol (EE).
Generic Allegra-D Approved. A combination of fexofenadine HCl and pseudoephedrine HCl in an extended-re-lease tablet (60 mg/120 mg) is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and chil-dren 12 years and older.
1. NAME OF THE MEDICINAL PRODUCT. EVRA 203 micrograms/24 hours + 33.9 micrograms/24 hours transdermal patch. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each 20 cm2 transdermal patch contains 6 mg norelgestromin (NGMN) and 600 micrograms ethinyl estradiol (EE).
FORMS, COMPOSITION AND PACKAGING section. INDICATIONS AND CLINICAL USE The EVRA® (norelgestromin and ethinyl estradiol) transdermal system is indicated for the prevention of pregnancy. The pharmacokinetic profile for the EVRA® transdermal system is different from that of an oral contraceptive.
This medicine’s product information is available in all official EU languages. Select 'available languages' to access the language you need. Product information documents contain: summary of product characteristics (annex I); manufacturing authorisation holder responsible for batch release (annex IIA);
EVRA contains two types of sex hormones, a progestogen called norelgestromin and an oestrogen called ethinyl estradiol. Because it contains two hormones, EVRA is called a ‘combined hormonal contraceptive’.
The EVRA (norelgestromin and ethinyl estradiol) transdermal system, with a contact surface area of 20 cm2, is a thin, matrix-type transdermal system consisting of three layers. Each transdermal system contains 6.0 mg norelgestromin and 0.60 mg ethinyl estradiol (EE).
